NYSEHealth CareDrug Manufacturers - Specialty & GenericSnapshot 2026-07-23
Reading PRGO? Create a free portfolio, then add this holding for ongoing Reports and tracking. Track it in a free portfolio. No credit card.
Create your account →A long-form read on the 1–3 year hold thesis. Slower and deeper than the daily snapshot — it refreshes only when the evidence moves.
This investment represents a turnaround situation where PRGO is trying to regain its footing after recent weak performance. The current thesis is cautious, given the company's loss-making status and elevated risks, but there is potential for recovery if management can execute effectively.
The market appears to have priced in a justified valuation that is cheap compared to peers. There is an expectations gap indicating that investors may not be anticipating significant improvements in performance in the near term.
Fundamentals are likely to remain under pressure in the near term, as management faces challenges with declining core net sales and a neutral management outlook. However, there are signs of market share gains in certain segments, which could provide some support.
The thesis hinges on key factors such as the performance of sector bellwethers and PRGO's ability to maintain its guidance. Additionally, any changes in management effectiveness and the outcomes of their debt reduction efforts will be crucial.
Over the next 1 to 3 years, PRGO's performance will depend on its execution of strategic priorities and external sector conditions. Not investment advice.
The most important moves since the prior daily snapshot.
Our read on the company is unchanged since the prior snapshot.
as of 2026-07-23
Specific, dated things to watch for, each with what would confirm it and what would prove it wrong.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
Why it matters: Earnings results will show if Perrigo can meet its full-year guidance after a challenging Q1.
Confirms one read:Q2 earnings report shows adjusted EPS within the guided range of $2.00 to $2.30.
Confirms the other:Q2 earnings report shows adjusted EPS below the guided range.
Why it matters: Earnings results will show if Perrigo can keep its full-year goals. This is important during tough times.
Confirms one read:Q2 earnings report shows revenue growth improving from Q1's decline of 7.2%.
Confirms the other:If Q2 earnings show more revenue decline or negative adjusted EPS, it will be a concern.
Why it matters: Core net sales growth signals whether Perrigo's market share gains can offset category headwinds. Investors will watch for signs of recovery.
Confirms:Core net sales growth between -3.0% and +1.0% for Q2 2026.
Disproves:Core net sales decline worse than -3.0% in Q2 2026.
Why it matters: Gaining market share can signal effective execution of the Three-S plan and drive revenue growth.
Confirms:Reported market share gains in the Self Care segment of at least 100 basis points.
Disproves:Market share declines or stagnation in the Self Care segment.
Why it matters: Gaining market share shows the strategy is working. This can help the company earn more money.
Confirms:Reported market share gains in key categories, especially in U.S. Store Brand and Women’s Health.
Disproves:No market share gains reported, or losses in key product categories.
Why it matters: Having a permanent CEO can stabilize leadership. This helps Perrigo's plans and builds investor trust.
Confirms:A permanent CEO has been announced. This person matches Perrigo's strategic goals.
Disproves:Interim leadership continues for over six months. There is still no permanent appointment.
Why it matters: Reducing debt can make finances more stable. This helps with future growth plans.
Confirms:They announced a debt cut of at least $300 million after selling Dermacosmetics.
Disproves:No major debt reduction is reported in the next financial update.
Why it matters: Earnings results will show how well the company is doing and its trends.
Confirms one read:Earnings beat expectations with revenue growth over 5%.
Confirms the other:Earnings miss expectations with revenue growth below 0%.
Why it matters: A new CEO can change the company's plans. This can affect how investors feel. Stability is important during this time.
Confirms:Announcement of a permanent CEO who has a strong track record in consumer health.
Disproves:If there is no permanent CEO in six months, uncertainty will continue.
Why it matters: Maintaining the dividend shows commitment to shareholders. A cut could signal deeper issues.
Confirms:Perrigo maintains its dividend at $0.29 per share in Q2.
Disproves:Perrigo cuts the dividend below $0.29 per share.
Why it matters: Successful debt reduction improves financial health and frees up resources for growth. This is key for investor confidence.
Confirms:Perrigo shows a big drop in total debt. This happened after selling the Dermacosmetics division.
Disproves:Total debt does not change or goes up. This is despite selling parts to reduce debt.
Why it matters: Completing the acquisition may help Perrigo grow. It could also improve its market position.
Confirms:The acquisition closes on schedule and is confirmed in a press release.
Disproves:The acquisition is postponed or called off.
Why it matters: The divestiture of the Dermacosmetics business is aimed at reducing debt. Progress here will show financial health.
Confirms:Total debt goes down to $3.6 billion after using the money from the sale.
Disproves:Total debt stays at $3.6 billion or goes up after the sale.
Why it matters: Better cash flow shows improved efficiency and stability. This is important for Perrigo's change.
Confirms:Operating cash flow turns positive in Q2 2026.
Disproves:Operating cash flow remains negative in Q2 2026.
Why it matters: Continued market share gains in U.S. store brand OTC products signal effective execution of the Three-S plan.
Confirms:U.S. store brand OTC volume share increases by more than 100 basis points.
Disproves:U.S. store brand OTC volume share declines or stagnates.
